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Summary
Angelman syndrome (AS) is caused by chromosome
15q11-q13 deletions of maternal origin, by paternal uni-
parental disomy (UPD) 15, by imprinting defects, and
by mutations in the UBE3A gene. UBE3A encodes a
ubiquitin-protein ligase and shows brain-specific im-
printing. Here we describe UBE3A coding-region mu-
tations detected by SSCP analysis in 13 AS individuals
or families. Two identical de novo 5-bp duplications in
exon 16 were found. Among the other 11 unique mu-
tations, 8 were small deletions or insertions predicted to
cause frameshifts, 1 was a mutation to a stop codon, 1
was a missense mutation, and 1 was predicted to cause
insertion of an isoleucine in the hect domain of the
UBE3A protein, which functions in E2 binding and ubi-
quitin transfer. Eight of the cases were familial, and five
were sporadic. In two familial cases and one sporadic
case, mosaicism for UBE3A mutations was detected: in
the mother of three AS sons, in the maternal grandfather
of two AS first cousins, and in the mother of an AS
daughter. The frequencies with which we detected mu-
tations were 5 (14%) of 35 in sporadic cases and 8
(80%) of 10 in familial cases.
Introduction
Angelman syndrome (AS [MIM 105830]), which is char-
acterized by severe mental retardation, lack of speech,
seizures, easily provoked smiling and laughter, ataxia,
and sleep disorder, is caused by a number of different
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genetic alterations involving chromosome 15q11-q13
(Williams et al. 1995). The phenotypic expression of
these chromosome 15 abnormalities is completely de-
pendent on the parent from whom the aberration is in-
herited. For instance, maternally inherited deletions of
15q11-q13 are responsible for 70% of AS cases, whereas
paternally inherited deletions of the same region cause
the phenotypically distinct Prader-Willi syndrome
(PWS). Some of the remaining 30% of AS cases are
caused by paternal UPD 15 (2%–3% of total AS cases)
and by imprinting defects with abnormal methylation
and gene expression patterns (2%–5%). Among the re-
maining nondeletion/non-UPD/non–imprinting-defect
AS patients, there are many instances of familial recur-
rence of AS that show an imprinted pattern of inheri-
tance, with phenotypic expression only after maternal
transmission. We and others have detected point mu-
tations in the UBE3A gene in some of these patients
(Kishino et al. 1997; Matsuura et al. 1997), which have
led to the conclusion that this is the 15q11-q13 gene
responsible for the AS phenotype.
Initial analysis of gene expression in lymphoblastoid
cell lines and fibroblasts from AS and PWS patients in-
dicated that UBE3A is not imprinted (Nakao et al.
1994). However, several subsequent reports have pro-
vided evidence for brain-specific imprinting of UBE3A
in both humans and mice (Albrecht et al. 1997; Rou-
geulle et al. 1997; Vu and Hoffman 1997). Using mice
with paternal UPD for the region of chromosome 7 con-
taining UBE3A, Albrecht et al. (1997) showed that its
imprinting is region specific, with almost undetectable
levels of expression in regions of the hippocampus, in
cerebellar Purkinje cells, and in mitral cells of the ol-
factory bulb in the UPD mice (Albrecht et al. 1997).
Maternal inheritance of UBE3A mutations therefore re-
sults in phenotypic abnormalities limited to the brain
because of brain-specific preferential expression of the
maternal allele.
How deficiency of the UBE3A protein in the brain
leads to the AS phenotype is unknown. UBE3A, as a
ubiquitin-protein ligase, catalyzes transfer of ubiquitin
Table 1
Primer Pairs Used for SSCP Analysis








7-1A TGTATTTCACTTTACAATGAC Intron 52 213
7-1B TAAAGTGTTCTAACCAAAGG Intron
5:
723-A TTTCTCTAGAAGTTTTTATAAC Intron 52 197
723-B ATCGCAGAAAATATGATCAC Intron
7:
E61-A GCTAACTGTTTCTCAATTGC Intron 52 105
E61-B ATAAGAACCACAGTCTCAAC Intron
8:
E6-8A CACTGTGCTTATTGTTTGAATG Intron 55 154
E6-8B TATCCATACGAAGAAAAGTTG Exon
E6-8C ATGAGTTTTGTGCTTCCTGT Exon 55 152
E6-8D TTTCGAGTTCTCAAGGTAAG Exon
E6-8E CCTCCAAGAAAGGAGCAAGC Exon 55 155
E6-8F TGGTTTTCAGGCAACAATTCTC Intron
9:
E6-9K AGAACTTTTTGCAACAGAGTAa Intron 55 164
E6-9L CCAATAACACGGATTAAAGG Exon
E6-9M GAAATTCTTGAATTATGTAGAGA Exon 55 197
E63-B GCAGCAGAACATGCAGCTTT Exon
E63-C GATGAAGACAAAGATGAAGAT Exon 52 153
E63-D ATCCACAGACACATCATCAG Exon
E63-E GACAACAATTTGCAAAAATTAG Exon 52 151
E63-F AGTCACATTCCACGTTAGGT Exon
E63-G GCCTTTCTCAATGCACTTGT Exon 52 153
E63-H AGCCATTTCCAGATATTCAG Exon
E63-I AGAATAGAAATCTCCACAGTC Exon 52 150
E63-J TCTCCATCATTCTCCGAATC Exon
E63-K GTGGTCTAAATACAATGCAG Exon 55 158
E63-L AGTAAACCATTTTCAAGCAC Exon
E63-M GATGCCATTGTTGCTGCTTC Exon 55 152
E63-N TCTTCTCCCAAAAGTTCCTG Exon
E6-9A CCCATCCCTGAGTCCAGCGA Exon 55 165
E6-9B CAGTGGTTCATTAATAAACTCT Exon
E6-9C ATTGTCGAAAACCACTTATC Exon 55 163
E6-9D CCCAAATTCTTTGTGACAGCA Exon
E6-9E ATGACATGTCCCTTTATATTG Exon 55 158
E6-9F TCACGTCTAACTTTGAGTCT Exon
E6-9G TTAGTTCAAGGACAGCAGTT Exon 55 119
E6-9H CCCCATTATTAGGTTTTTAATCT Intron
10:
E6-10A GCAATCATCTTCTTTTCATGTT Intron 55 217
E6-10B CGACACCATAATCACATTAC Intron
(Continued)
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E6-11A AGTCCTTAATAAAATACAAAAGT Intron 55 150
E6-11B ACCCAGTACTATGCCAATCA Exon
E6-11C AACTGAGGGTCAGTTTACTC Exon 55 175
E6-11D GAATTAAAAAAATGACAAAGAAC Intron
12:
E6-12A TGTTGTATTTTGTAGTTCTATGG Intron 52 172
E6-12B AGATCATACATCATTGGGTTAC Exon
E6-12C GATCACTTTCCAGATATCACAG Exon 52 143
E6-12D TTAATGAAGAGACAAAATGTGAC Intron
13:
E6W-A GAAGTTCTTGTGATTAATGTb Intron 52 137
E6W-B CTTTAAGGGAGATTCATTGG Exon
E6W-C AAAACAGTTCAAGGCTTTTC Exon 52 145
E6W-D CGATACATGACTTTTTGCAG Intron
14:
E6-14F AGTAGTATAGCAGATAACTAAGAC Intron 52 164
E6-14R CCCTTTGGTGAATCAAATCTTCC Intron
15:
E6Y-A TGAATGCCAAACTGAAACCA Intron 52 130
E6Y-C CCCACAGGTGCTCTGTCT Exon
E6Y-B TTCGGTAGGTATACAGTCAC Intron 52 147
E6Y-D AACAGAAAAGACTCTTCTTG Exon
16:
E6Z-A CCATGACTTACAGTTTTCCT Intron 55 277
E6Z-B TGGGACACTATCACCACCAA 3′ UTR
a The primer used in this study had an extra G erroneously inserted after the second base of
this primer; the sequence shown in this table reflects the correct genomic sequence (H. Kokkonen
1997, personal communication).
b The primer used in this study had an extra T erroneously inserted after the fourth base of this
primer; the sequence shown in this table reflects the correct genomic sequence (H. Kokkonen 1997,
personal communication).
to substrates, which are thereby targeted for degradation
by the proteasome (Huibregtse et al. 1993a). The two
known substrates of UBE3A are p53, whose ubiquitin-
ation by UBE3A is dependent on the E6 protein of high-
risk human papillomaviruses (HPVs), and HHRAD23A,
a homolog of the yeast Rad23 protein, whose ubiqui-
tination is E6 independent (Kumar et al. 1997). There
is no evidence for ubiquitination of p53 by UBE3A in
cells not infected with HPV, and it is unknown whether
HHRAD23A plays a role in the pathogenesis of AS.
In this report, we describe mutation analysis of the
UBE3A coding region in a group of 35 sporadic and 10
familial AS cases. We have found mutations in 13 of
these cases. Our results demonstrate that alterations
throughout the UBE3A coding region can cause AS and
that these mutations can include chain-terminating, mis-
sense, and amino acid–insertion mutations. We also pro-
vide evidence of mosaicism for UBE3A mutations in the
mothers and in the grandfathers of AS individuals.
Material and Methods
Patients
Patients either were examined by one of us or were
referred by clinical geneticists, with a diagnosis of either
definite or probable AS. Deletion, UPD, and imprinting
mutations had been excluded in all of the patients by
some combination of FISH analysis, methylation anal-
ysis, and polymorphism analysis for UPD. Informed con-
sent for mutation analysis was obtained from all
families.
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SSCP Analysis
We performed SSCP analysis using genomic DNA
from patients and the primers listed in table 1. PCR
reactions for SSCP analysis were carried out with the
annealing temperatures listed in table 1. PCR products
from exon 16 were cleaved with MspI before electro-
phoresis. Products were separated on 0.5# Mutation
Detection Enhancement gels (A-T Biochemical) contain-
ing 10% glycerol at room temperature, or without glyc-
erol at 4C, and were visualized by autoradiography. All
SSCP band shifts were verified by repetition of the PCR
and SSCP. Abnormal bands were cut out, eluted in water,
and reamplified by PCR with the original primers for
sequencing. Parents and other family members were
tested for known UBE3A mutations by SSCP analysis.
Linkage Analysis
Linkage analysis in family 5 was done as described
elsewhere (Wagstaff et al. 1993).
DNA Sequencing
PCR products were sequenced on an ABI 373A or
ABI 377 automated DNA sequencer. In cases where both
PCR primers were from the same exon, the sequence of
the mutant allele was compared with the UBE3A se-
quence and with the sequences of two processed pseu-
dogenes of UBE3A (Kishino and Wagstaff 1998), to ver-
ify that the mutation affects UBE3A and not one of the
pseudogenes.
Results
We analyzed 45 cases with diagnoses of either definite
or probable AS, for mutations in the coding regions of
UBE3A. Thirty-five of the nondeletion/non-UPD/
non–imprinting-defect AS cases were sporadic, and 10
were from families with more than one AS individual
(fig. 1). The SSCP analysis included exons 4, 5, and 7–16,
which include the known open reading frames of UBE3A
(Yamamoto et al. 1997; Kishino and Wagstaff 1998).
Among this group, mutations were detected in 13 cases:
there were 12 unique mutations, with 1 mutation present
in two individuals (table 2). (These mutations include
the two described by Kishino et al. 1997.) Eight of the
mutations were insertions, deletions, or splice mutations
predicted to cause frameshifting and premature termi-
nation of translation. The splice mutation in intron 9
(family 2) was shown to cause abnormal splicing of
UBE3A RNA in a lymphoblastoid cell line established
from one of the brothers (data not shown). One mu-
tation (family 4) produced a stop codon. The mutation
in family 5 is predicted to cause a serine to proline
change at position 349, and another mutation (family
7) is predicted to cause insertion of an isoleucine at po-
sition 802. This insertion mutation was not present in
82 unrelated normal control individuals. Mutations
were detected in exons 8, 9, 10, 12, 15, and 16.
In families with more than one AS individual (i.e.,
families 2, 3, 6, 7, 8, 10, and 11), all affected individuals
in a family were heterozygous for the same mutation,
as were their phenotypically normal mothers (for family
5, see below). The mothers’ normal phenotypes are pre-
sumably due to inheritance of the UBE3A mutations
from their fathers. This transmission of a UBE3A mu-
tation from father to normal daughter to AS child was
shown directly in family 11 (data not shown).
Two variants were identified that are probably not
pathogenic. Three patients were heterozygous for the
A178T missense mutation; in the patient described by
Matsuura et al. (1997) and in one patient examined by
us, the mutation was inherited from the father, indicating
that it is not causative of AS. The two AS sisters in family
8, in addition to having the 2527insA mutation, were
both heterozygous for a GrA transition at position 702,
leading to R39H substitution. This base change was in-
herited from their father.
Family 5, in which the S349P missense mutation was
detected in three AS brothers, had originally been ana-
lyzed with polymorphic microsatellite markers flanking
UBE3A. This analysis (fig. 2) gave the unexpected result
that two AS brothers shared the same maternal haplo-
type with an unaffected brother; the third AS brother
had a crossover between D15S11 and GABRB3, which
flank UBE3A. SSCP analysis with primers E63-K and
E63-L showed the same abnormal band in the three AS
brothers but not in their normal siblings. The pheno-
typically normal mother showed a faint abnormal band
(!5% of wild-type band density), demonstrating mo-
saicism for the mutation. Sequence analysis of the ab-
normal band showed a TrC transition at position 1631,
predicted to change serine to proline at position 349.
The mother’s apparent somatic and germline mosaicism
accounts for the presence of the same maternal haplo-
type in normal and AS siblings.
In family 11, in which two brothers and their maternal
first cousin with AS were heterozygous for a 14-bp de-
letion in exon 9, their normal mothers also were het-
erozygotes for the same mutation. Their maternal grand-
father’s blood DNA showed only a very faint SSCP band
corresponding to the mutation (data not shown), indi-
cating that he also is mosaic, both in blood and germline,
for this deletion. Similarly, in family 12, with a single
affected child bearing a single-base insertion in exon 8,
the mother showed a very faint SSCP band correspond-
ing to the mutant allele, indicating mosaicism. In the
other four families with a single affected child, the moth-
ers were not heterozygotes, and there was no evidence
of mosaicism.
We have compared clinical characteristics of AS in-
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Figure 1 Pedigrees of familial AS cases. Genotypes are shown for affected individuals and for unaffected individuals who have been
tested. Mutations are denoted by the minus sign (); the mutation in each family is described in table 1. Mosaicism is indicated by “mos.”
dividuals from 11 families with UBE3A mutations pre-
dicted to cause premature chain termination (families
1–4, 6, and 8–13) with those of AS individuals with
either missense or amino acid–insertion mutations (fam-
ilies 5 and 7). Approximately half of the individuals in
each group showed microcephaly (occipitofrontal cir-
cumference less than second percentile). In both groups,
almost all AS individuals had a clinical history of sei-
zures. The frequency of AS individuals who walked in-
dependently before 24 mo of age was 5 (28%) of 18 in
the chain-terminating–mutation group and 0 of 5 in the
missense/amino acid–insertion group.
Discussion
We have found intragenic mutations of UBE3A in 13
individuals and families with AS not caused by large
deletion, UPD, or imprinting mutations. These muta-
tions, taken together with the balanced inversion break-
point between UBE3A exons 1 and 2 (Greger et al. 1997;
Kishino et al. 1997), indicate that intragenic alterations
spanning essentially the entire 120-kb UBE3A gene cause
AS when transmitted maternally. Although there is a
complex pattern of alternative splicing in the 5′ UTR of
UBE3A (Rougeulle et al. 1997; Yamamoto et al. 1997;
Kishino and Wagstaff 1998), all of these mutations are
predicted to affect all of the known splice products.
Most of the mutations that we have found are pre-
dicted to lead to premature stop codons in UBE3A
mRNA. These mutations probably lead to their phe-
notypic effects both by reducing UBE3A mRNA con-
centrations and by causing any translation products to
be catalytically inactive because of the importance of the
extreme C terminus of the UBE3A protein for its cata-
lytic function (Huibregtse et al. 1995). The two
non–chain-terminating mutations include S349P in three
AS brothers and I802ins in two cousins. The S349P
change is within the minimal region of UBE3A that can
direct E6-dependent association with p53 (Huibregtse et
al. 1993b). Although there is no evidence for p53 as a
UBE3A substrate in non–HPV-infected cells, this region
is likely to play a role in the binding of non–E6-depen-
dent substrates whose ubiquitination may play a role in
the pathogenesis of AS. The isoleucine duplication
(I802ins) lies within the hect domain that is conserved
among a number of E3 ubiquitin-protein ligases from
diverse organisms (Huibregtse et al. 1995). The hect do-
main functions in E2 binding and in ubiquitin transfer
(Kumar et al. 1997). This duplication is 16 amino acids
N-terminal to the cysteine residue to which ubiquitin is
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Table 2
UBE3A Mutations in AS Individuals and Families





1 Sporadic (de novo) Exon 16 3086ins5 Frameshift Proband
2 Familial Intron 9 IVS9-8ArG Frameshift Two brothers
3 Familial Exon 9 1522delG Frameshift Brother and sister
4 Sporadic (de novo) Exon 9 2030CrT R482X Proband
5 Familial Exon 9 1631TrC S349P Three brothers
6 Familial Exon 16 3033insA Frameshift Two maternal first
cousins
7 Familial Exon 15 2992ins3 I802ins Two maternal second
cousins
8 Familial Exon 12 2527insA Frameshift Two sisters
9 Sporadic (de novo) Exon 10 2230del26insA Frameshift Proband
10 Familial Exon 9 2037del10 Frameshift Brother and sister




Exon 8 645insA Frameshift Proband
13 Sporadic (de novo) Exon 16 3086ins5 Frameshift Proband
NOTE.—Nucleotide and amino acid positions are according to GenBank U84404.
Figure 2 Linkage and SSCP results in family 5. The pedigree,
with three AS brothers and three normal brothers, is shown together
with genotypes for loci D15S11, GABRB3, and GABRA5. The ma-
ternal haplotype DBB present in two AS brothers and one normal
brother is boxed; the third AS brother has a crossover between D15S11
and GABRB3 and has only the centromeric marker D of that haplo-
type. The lower panel shows a portion of the SSCP gel on the family,
created by the use of primers E63-K and E63-L and a gel run at 4C
with no glycerol. The three normal brothers and the father have only
the upper (normal) band; the three AS brothers have upper and lower
(mutant) bands of equal intensity; and the mother has a lower band
of !5% of the intensity of the upper band, demonstrating mosaicism
for the UBE3A S349P mutation.
covalently linked before its transfer to substrates. How-
ever, although one of the two isoleucine residues at this
site in the normal protein is conserved among many hect
family members, this portion of the protein is otherwise
not highly conserved in the hect family. Determining the
effects of these amino acid–sequence changes on UBE3A
function will be possible with use of in vitro assays with
E6-dependent and independent substrates. As more
UBE3A substrates are identified, these mutations may
facilitate the determination of which substrates are im-
portant in the pathogenesis of AS.
We have found mutations in 5 (14%) of 35 sporadic
AS cases and in 8 (80%) of 10 familial cases. These cases
either were examined by one of the authors or were
considered by referring physicians to have either a def-
inite or a probable clinical diagnosis of AS. The reason
for this significant discrepancy between mutation fre-
quencies in the sporadic versus familial cases is unclear.
It is unlikely to be because of different efficiencies of
mutation detection in the two groups: we have found
deletions, insertions, and base substitutions in both
groups, and there is no reason to suspect that SSCP is
more sensitive to the mutations in familial cases than to
those in sporadic cases. A second possibility is that the
diagnosis of AS is more likely to be accurate in the fa-
milial cases than in the sporadic cases. This could be
true if one or more disorders unrelated to 15q11-q13
can cause an AS-like phenotype and can occur predom-
inantly in sporadic form. There is no published evidence
for locus heterogeneity in AS.
We have found evidence for mosaicism in three fam-
ilies: in one case, three of the six sons of a mosaic mother
were affected with AS; in the second case, two of the
three daughters of a mosaic male inherited the mutation
and had AS offspring; and in the third case, one AS child
was born to a mosaic mother. It is important to consider
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the possibility of mosaicism when providing genetic
counseling in families with nondeletion AS offspring. In
particular, the fact that an AS child and a normal sibling
have inherited the same maternal haplotype does not
exclude the possibility of recurrence of AS to their
mother.
We have compared the effects of chain-terminating
mutations of UBE3A to the effects of missense or amino
acid–insertion mutations on clinical characteristics of AS
individuals. We have found no significant difference be-
tween the two groups with respect to incidence of mi-
crocephaly, incidence of seizure disorder, or age of walk-
ing independently. This lack of correlation between
mutation type and phenotype is not unexpected given
that our analysis was limited to individuals with a def-
inite or probable clinical diagnosis of AS. Non–chain-
terminating mutations among this class of patients will
probably be mutations whose effects on UBE3A function
are as severe as those of chain-terminating mutations.
Matsuura et al. (1997) described a UBE3A missense mu-
tation (C21Y) transmitted from a normal mother to a
child with features milder than those of classical AS, and
other missense mutations will probably be detected
among patients with similarly mild features.
The detection of UBE3A mutations in some nonde-
letion/non-UPD/non–imprinting-defect AS individuals
and families answers some questions about the patho-
genesis of AS and provides the possibility of accurate
recurrence-risk counseling and prenatal diagnosis for
some families. However, these findings raise many other
questions. First, UBE3A mutation analysis increases the
percentage of AS individuals in whom one can make a
molecular diagnosis from ∼75% to ∼80%; what is the
etiology of AS in the remaining 20%, and what is the
recurrence risk? What are the substrates of UBE3A in
brain, and what are the biochemical changes in AS brain
that lead to the characteristic phenotype? Are the phe-
notypic abnormalities caused exclusively by complete
lack of UBE3A expression in certain brain regions, or
is the phenotype also due in part to brain regions where
UBE3A expression is reduced but not absent? If AS is
caused by failure of ubiquitin-mediated degradation of
certain substrates, presumably with accumulation of
those substrates, why does the disorder not show a neu-
rodegenerative course, rather than the static course ob-
served? Providing answers to these questions will require
continued analysis of UBE3A alterations in AS patients,
together with production of animal models in which to
test hypotheses generated from human studies.
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